References
Teksin ZS, Hom K, Balakrishnan A, Polli JE. Apparent ion pair-mediated transport of metoprolol across a three lipid component PAMPA system. J Control Rel. 2006;116:50–7.
Kerns EH, Li D, Petusky S, Farris M, Ley R, Jupp P. Combined application of parallel artificial membrane permeability assay and Caco-2 permeability assays in drug discovery. J Pharm Sci. 2004;93(6):1440–53.
Avdeef A, Strafford M, Block E, Balogh MP, Chambliss W, Khan I. Drug absorption in vitro model: filter-immobilized artificial membranes. 2. Studies of the permeability properties of lactones in piper methysticum Forst. Eur J Pharm Sci. 2001;14:271–80.
Wohnsland F, Faller B. Permeability pH profile and high-throughput alkane/water log P artificial membranes. J Med Chem. 2001;44:923–30.
Seo PR, Teksin ZS, Kao JPY, Polli JE. Lipid composition effect on permeability across PAMPA. Eur J Pharm Sci. 2006;29:259–68.
Sugano K, Nabuchi Y, Machida M, Asoh Y. Permeation characteristics of a hydrophilic basic compound across a bio-mimetic artificial membrane. Int J Pharm. 2004;275:271–78.
Palm K, Luthman K, Ros J, Grasjo J, Artursson P. Effect of molecular charge on intestinal epithelial drug transport: pH-dependent transport of cationic drugs. J Pharmacol Exp Ther. 1999;291:435–43.
Hwang K, Martin NE, Jiang L, Zhu C. Permeation prediction of M100240 using the parallel artificial membrane permeability assay. J Pharm Sci. 2003;6(3):315–20.
Polli JE, Ginski MJ. Human drug absorption kinetics and comparison to Caco-2 monolayer permeabilities. Pharm Res. 1998;15:47–52.
Tolle-Sander S, Grill A, Joshi H, Kapil R, Persiani S, Polli JE. Characterization of dexloxiglumide in vitro biopharmaceutic properties and active transport. J Pharm Sci. 2003;92:1968–80.
Bermejo M, Avdeef A, Ruiz A, Nalda R, Ruell JA, Tsinman O, et al. PAMPA-a drug absorption in vitro model 7. Comparing rat in situ, Caco-2, and PAMPA permeability of fluoroquinolones. Eur J Pharm Sci. 2004;21:429–41.
Fujikawa M, Ano R, Nakao K, Shimizu R, Akamatsu M. Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: application to prediction of Caco-2 cell permeability. Bioorg Med Chem. 2005;13:4721–732.
Avdeef A, Artursson P, Neuhoff S, Lazorova L, Grasjö J, Tavelin S. Caco-2 permeability of weakly basic drugs predicted with the double-sink PAMPA pKa(flux) method. Eur J Pharm Sci. 2005;24:333–49.
Masungi C, Mensch J, Van Dijck A, Borremans C, Willems B, Mackie C, et al. Parallel artificial membrane permeability assay (PAMPA) combined with a 10-day multiscreen Caco-2 cell culture as a tool for assessing new drug candidates. Pharmazie. 2008;63:194–99.
Koljonen M, Rousu K, Cierny J, Kaukonen A, Hirvonen J. Transport evaluation of salicylic acid and structurally related compounds across Caco-2 cell monolayers and artificial PAMPA membranes. Eur J Pharm Biopharm. 2008;70:531–8.
Corti G, Maestrelli F, Cirri M, Zerrouk N, Mura P. Development and evaluation of an in vitro method for prediction of human drug absorption II. Demonstration of the method suitability. Eur J Pharm Sci. 2006;27:354–62.
Lipoid E 80 product brochure. Lipoid GmbH, Ludwigshafen. 2006.
Guidance for Industry, Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System. August 2000, CDER/FDA. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070246.pdf (accessed 1/12/2010).
Vogelpoel H, Welink J, Amidon GL, Junginger HE, Midha KK, Moller H, et al. Biowaiver monographs for immediate release solid oral dosage forms based on biopharmaceutics classification system (BCS) literature data: verapamil hydrochloride, propranolol hydrochloride, and atenolol. J Pharm Sci. 2004;93:1945–56.
de Miranda P, Blum MR. Pharmacokinetics of acyclovir after intravenous and oral administration. J Antimicrob Chemother. 1983;12(Suppl B):29–37.
Chiou WL, Jeong HY, Chung SM, Wu TC. Evaluation of using dog as an animal model to study the fraction of oral dose absorbed of 43 drugs in humans. Pharm Res. 2000;17(2):135–40.
Artursson P, Karlsson J. Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2)cells. Biochem Biophys Res Com. 1991;175(3):880–5.
Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE et al. MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci. 1999;88(1):28–33.
Zakeri-Milania P, Valizadeha H, Tajerzadehc H, Azarmia Y, Islambolchilara Z, Barzegara S et al. Predicting human intestinal permeability using single-pass intestinal perfusion in rat. J Pharm Pharm Sci. 2007;10:368–79.
Dollery Sir C. Therapeutic drugs. Livingstone: Churchill; 1991.
Ritschel WA, Brady ME, Tan HS. First-pass effect of coumarin in man. Int J Clin Pharmacol Biopharm. 1979;17(3):99–103.
Lima JJ, Haughey DB, Leier CV. Disopyramide pharmacokinetics and bioavailability following the simultaneous administration of disopyramide and 14Cdisopyramide. J Pharm Biopharm. 1984;12(3):289–313.
Hardman JG, Limbird LE. Goodman and Gilman’s The Pharmacological Basis of Therapeutics. 9th ed. New York: McGraw-Hill; 1996.
Ponto LL, Schoenwald RD. Furosemide (frusemide). A pharmacokinetic/pharmacodynamic review (Part I). Clin Pharmacokin. 1990;18(5):381–408.
Zhu C, Jiang L, Chen TM, Hwang KK. A comparative study of artificial membrane permeability assay for high-throughput profiling of drug absorption potential. Eur J Med Chem. 2002;37(5):399–407.
Roberfroid MB. Concepts in functional foods: The case of inulin and oligofructose. J Nutrition. 1999;129(7):1398–401.
Li C, Wainhaus S, Uss A, Cheng K. High-throughput screening using Caco-2 Cell and PAMPA systems. In: Ehrhardt C, Kim KJ, editors. In drug absorption studies in situ, in vitro and in silico models. Springer US; 2008. p. 418–429.
Yee S. In vitro permeability across Caco-2 cells (colonic) can predict in vivo (small intestinal) absorption in man-fact or myth. Pharm Res. 1997;14(6):763–6.
Yazdanian M, Glynn SL, Wright JL, Hawi A. Correlating partitioning and Caco-2 cell permeability of structurally diverse small molecular weight compounds. Pharm Res. 1998;15(9):1490–4.
Grant SM, Langtry HD, Brogden RN. Ranitidine: An updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in peptic ulcer disease and other allied diseases. Drugs. 1989;37(6):801–70.
Hendeles L, Weinberger M, Bigley L. Absolute oral bioavailability of oral theophylline. Am J Hosp Pharm. 1977;34:525–7.
Balimane PV, Han YH, Chong S. Current industrial practices of assessing permeability and P-glycoprotein interaction. AAPS J. 2006;8(1):E1–13.
Acknowledgments
Z.S. Teksin was supported by NATO Science Fellowship Program by The Scientific and Technical Research Council of Turkey (TUBITAK) and Gazi University in Ankara, Turkey. This work was support in part by National Institutes of Health grant DK67530.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Teksin, Z.S., Seo, P.R. & Polli, J.E. Comparison of Drug Permeabilities and BCS Classification: Three Lipid-Component PAMPA System Method versus Caco-2 Monolayers. AAPS J 12, 238–241 (2010). https://doi.org/10.1208/s12248-010-9176-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1208/s12248-010-9176-2